OpGen (OPGN) Ending Cash Position : $0.79 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OpGen Ending Cash Position?

OpGen's Ending Cash Position for the quarter that ended in Sep. 2023 was $0.79 Mil.

OpGen's quarterly Ending Cash Position declined from Mar. 2023 ($7.54 Mil) to Jun. 2023 ($3.73 Mil) and declined from Jun. 2023 ($3.73 Mil) to Sep. 2023 ($0.79 Mil).

OpGen's annual Ending Cash Position increased from Dec. 2020 ($14.11 Mil) to Dec. 2021 ($36.63 Mil) but then declined from Dec. 2021 ($36.63 Mil) to Dec. 2022 ($7.94 Mil).

OpGen Ending Cash Position Historical Data

The historical data trend for OpGen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Ending Cash Position Chart

OpGen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

Get a 7-Day Free Trial

4.74

2.89

14.11

36.63

7.94

OpGen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Ending Cash Position	Get a 7-Day Free Trial															10.70	7.94	7.54	3.73	0.79

OpGen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

OpGen's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	36.633	+	-28.697
	=	7.94

OpGen's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3.734	+	-2.949
	=	0.79

OpGen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of OpGen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

OpGen (OPGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (NAS:OPGN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

650:Germany

Address

9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850

Website

https://www.opgen.com

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

Executives

Yvonne Schlaeppi	director	600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher	officer: Chief Operating Officer	9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber	officer: Chief Finanical Officer	MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht	director, officer: Chief Executive Officer	9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones	director, officer: Chief Executive Officer	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes	director	C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation	10 percent owner	MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto	director	C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro	officer: Chief Information Officer	C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec	officer: Chief Financial Officer	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc	10 percent owner	P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea	director	6480 DOBBIN ROAD, COLUMBIA MD 21045